⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25066939 | 0.86 | NLRP3 (0.36) | — | |
| SCHEMBL23692337 | 0.84 | MLYCD (0.33) | — | |
| SCHEMBL23692177 | 0.78 | NLRP3 (0.38) | — | |
| SCHEMBL20698750 | 0.78 | — | — | |
| SCHEMBL25066950 | 0.77 | NLRP3 (0.47) | — | |
| SCHEMBL25139057 | 0.73 | NLRP3 (0.32) | — | |
| SCHEMBL23692367 | 0.70 | PSEN1 (0.37) | — | |
| SCHEMBL20698996 | 0.70 | NLRP3 (0.32) | — | |
| SCHEMBL25067057 | 0.69 | NLRP3 (0.34) | — | |
| SCHEMBL20699085 | 0.68 | NLRP3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| US-20210230129-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |